Glomerular handling of native albumin in the presence of circulating modified albumins by the normal rat kidney

American Journal of Physiology - Renal Physiology

Volumn 289, Issue 6 58-6, 2005, Pages

  Londono, I ^a   Bendayan, M ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Amadori; Diabetes; Immunocytochemistry

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; BOVINE SERUM ALBUMIN; GLUCOSE; HAPTEN; LYSINE; SERUM ALBUMIN;

ACETYLATION; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMICAL REACTION; DIABETES MELLITUS; ENDOCYTOSIS; EVALUATION; GLOMERULOPATHY; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION; GLYCATION; HYPERGLYCEMIA; IMMUNOCYTOCHEMISTRY; IMMUNOGOLD LABELING; KIDNEY TUBULE EPITHELIUM; METHYLATION; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; RAT;

EID: 27944444602     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00027.2005     Document Type: Article

References (65)

1. Aaltonen P, Luimula P, Astrom E, Palmen T, Gronholm T, Palojoki E, Jaakkola I, Ahola H, Tikkanen I, and Holthofer H. Changes in the expression of nephrin gene and protein in experimental diabetic nephropathy. Lab Invest 81: 1185-1190, 2001.
2. Amore A, Cirina P, Mitola S, Peruzzi L, Gianoglio B, Rabbone I, Sacchetti C, Cerutti F, Grillo C, and Coppo R. Nonenzymatically glycated albumin (Amadori adducts) enhances nitric oxide synthase activity and gene expression in endothelial cells. Kidney Int 51: 27-35, 1997.
3. Asanuma K and Mundel P. The role of podocytes in glomerular pathobiology. Clin Exp Nephrol 1: 255-259, 2003.
4. Bendayan M. Immunocytochemical detection of advanced glycated end products in rat renal tissue as a function of age and diabetes. Kidney Int 54: 438-447, 1998.
5. Bendayan M, Gingras D, and Charest P. Distribution of endogenous albumin in the glomerular wall of streptozotocin-induced diabetic rats as revealed by high-resolution immunocytochemistry. Diabetologia 29: 868-875, 1986.
6. Bendayan M and Londono I. Reabsorption of native and glycated albumin by renal proximal tubular epithelial cells. Am J Physiol Renal Fluid Electrolyte Physiol 271: F261-F268, 1996.
7. Brenner BM and Hostetter TH. Mechanisms of glomerular barrier function. Contrib Nephrol 26: 9-16, 1981.
8. Brownlee M, Vlassara H, and Cerami A. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 101: 527-537, 1984.
9. 1 production and protein kinase C activity in glomerular endothelial cells. Kidney Int 59: 673-681, 2001.
10. Chen S, Cohen MP, and Ziyadeh FN. Amadori-glycated albumin in diabetic nephropathy: pathophysiologic connections. Kidney Int Suppl 77: S40-S44, 2000.
11. Chiarelli F, Cipollone F, Romano F, Tumini S, Costantini F, di Ricco L, Pomilio M, Pierdomenico SD, Marini M, Cuccurullo F, and Mezzetti A. Increased circulating nitric oxide in young patients with type 1 diabetes and persistent microalbuminuria: relation to glomerular hyperfiltration. Diabetes 49: 1258-1263, 2000.
12. Cohen MP. Nonenzymatic glycation and enhanced polyol pathway activity in the pathogenesis of diabetic nephropathy. In: Diabetes and the Kidney, edited by Heiland A, Koch KM, and Heidbreder E. Basel: Karger, 1989, p. 59-76.
13. 1 production in macrophage RAW cells. J Lab Clin Med 141: 242-249, 2003.
14. Cohen MP and Ziyadeh FN. Role of Amadori-modified nonenzymatically glycated serum proteins in the pathogenesis of diabetic nephropathy. J Am Soc Nephrol 7: 183-190, 1996.
15. Cohen MP, Ziyadeh FN, Lautenslager GT, Cohen JA, and Shearman CW. Glycated albumin stimulation of PKC-β activity is linked to increased collagen IV in mesangial cells. Am J Physiol Renal Physiol 276: F684-F690, 1999.
16. Cooper ME and Gilbert RE. Pathogenesis, prevention and treatment of diabetic nephropathy. In: Comprehensive Clinical Nephrology, edited by Johnson RJ and Feehally J. London: Mosby, 2000, section 6, chapter 35, p. 35.1-35.12.
17. Deen WM, Bridges CR, and Brenner BM. Biophysical basis of glomerular permselectivity. J Membr Biol 71: 1-10, 1983.
18. Desjardins M and Bendayan M. Ultrastructural distribution of endogenous IgGs in the glomerular wall of control and diabetic rats. Histochem 721: 731-742, 1989.
19. Donnelly SM. Accumulation of glycated albumin in end-stage renal failure: evidence for the principle of "physiological microalbuminuria". Am J Kidney Dis 28: 62-66, 1996.
20. Doublier S, Salvidio G, Lupia E, Ruotsalainen V, Verzola D, Deferrari G, and Camussi G. Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin, and angiotensin II. Diabetes 52: 1023-1030, 2003.
21. Doucet M, Londono I, Gomez-Pascual A, and Bendayan M. Glomerular basement membrane selective permeability in short-term streptozotocin-induced diabetic rats. Int J Exp Diabetes Res 1: 19-30, 2000.
22. Farquhar MG. Editorial: the primary glomerular filtration barrier-basement membrane or epithelial slits? Kidney Int 8: 197-211, 1975.
23. Ghitescu L and Bendayan M. Hapten-tagged plasma proteins as immunocytochemical probes for the study of vascular permeability. Microsc Res Tech 22: 392-401, 1992.
24. Ghitescu L and Bendayan M. Transendothelial transport of serum albumin: a quantitative immunocytochemical study. J Cell Biol 117: 745-755, 1992.
25. Ghitescu L, Desjardins M, and Bendayan M. Immunocytochemical study of glomerular permeability to anionic, neutral and cationic albumins. Kidney Int 42: 25-32, 1992.
26. Ghitescu L and Robert M. Diversity in unity: the biochemical composition of the endothelial cell surface varies between the vascular beds. Microsc Res Tech 57: 381-389, 2002.
27. Graham RC Jr and Karnovsky MJ. Glomerular permeability. Ultrastructural cytochemical studies using peroxidases as protein tracers. J Exp Med 124: 1123-1134, 1966.
28. Hansen B, Arteta B, and Smedsrod B. The physiological scavenger receptor function of hepatic sinusoidal endothelial and Kupffer cells is independent of scavenger receptor class A type I and II. Mol Cell Biochem 240: 1-8, 2002.
29. Holvoet P, Perez G, Zhao Z, Brouwers E, Bernar H, and Collen D. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest 95: 2611-2619, 1995.
30. Horiuchi S. The liver is the main site for metabolism of circulating advanced glycation end products. J Hepatol 36: 123-125, 2002.
31. Hostetter TH. Diabetic nephropathy: metabolic vs. hemodynamic considerations. Diabetes Care 15: 1205-1215, 1992.
32. Ido Y, Chang KC, Lejeune WS, Bjercke RJ, Reiser KM, Williamson JR, and Tilton RG. Vascular dysfunction induced by AGE is mediated by VEGF via mechanisms involving reactive oxygen species, guanylate cyclase, and protein kinase C. Microcirculation 8: 251-263, 2001.
33. Islam M, Qamar S, and Tayyab S. Involvement of lysine residues of goat serum albumin in high-affinity binding of bilirubin. Biochim Biophys Acta 1205: 171-177, 1994.
34. Jakus V and Rietbrock N. Advanced glycation end-products and the progress of diabetic vascular complications. Physiol Res 53: 131-142, 2004.
35. Khan MM and Tayyab S. Understanding the role of internal lysine residues of serum albumins in conformational stability and bilirubin binding. Biochim Biophys Acta 1545: 263-277, 2001.
36. Klapper MH and Klotz IM. Acylation with dicarboxylic acid anhydrides. Methods Enzymol 25: 531-536, 1972.
37. Kowluru A, Kowluru R, Bitensky MW, Corwin EJ, Solomon SS, and Johnson JD. Suggested mechanism for the selective excretion of glucosylated albumin. The effects of diabetes mellitus and aging on this process and the origins of diabetic microalbuminuria. J Exp Med 166: 1259-1279, 1987.
38. Layton GJ and Jerums G. Effect of glycation of albumin on its renal clearance in normal and diabetic rats. Kidney Int 33: 673-676, 1988.
39. Levine RL. Fluorescence-quenching studies of the binding of bilirubin to albumin. Clin Chem 23: 2292-2301, 1977.
40. Londono I and Bendayan M. Temporary effects of circulating Amadori products on glomerular filtration properties in the normal mouse. Am J Physiol Renal Physiol 280: F103-F111, 2001.
41. Londono I, Ghitescu L, and Bendayan M. Glomerular handling of circulating glycated albumin in the normal mouse kidney. Am J Physiol Renal Fluid Electrolyte Physiol 268: F913-F921, 1995.
42. Mayhan WG and Sharpe GM. Aminoguanidine suppresses basal macromolecular extravasation during diabetes mellitus. Microvasc Res 59: 52-60, 2000.
43. Means GE and Feeney RE. Reductive alkylation of amino groups in proteins. Biochemistry 7: 2192-2201, 1968.
44. Mir MM, Fazili KM, and Abul Qasim M. Chemical modification of buried lysine residues of bovine serum albumin and its influence on protein conformation and bilirubin binding. Biochim Biophys Acta 1119: 261-267, 1992.
45. Nagai R and Horiuchi S. Application of monoclonal antibody libraries for the measurement of glycation adducts. Biochem Soc Trans 31: 1438-1440, 2003.
46. Ohashi T, Uchida K, Uchida S, Sasaki S, and Nihei H. Intracellular mislocalization of mutant podocin and correction by chemical chaperones. Histochem Cell Biol 119: 257-264, 2003.
47. Petersen CE, Ha CE, Harohalli K, Feix JB, and Bhagavan NV. A dynamic model for bilirubin binding to human serum albumin. J Biol Chem 275: 20985-20995, 2000.
48. Puurunen M, Mänttäri M, Manninen V, Tenkanen L, Alfthan G, Ehnholm C, Vaarala O, Aho K, and Palosuo T. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 154: 2605-2609, 1994.
49. Rennke HG, Olson JL, and Venkatachalam MA. Glomerular filtration of macromolecules: normal mechanisms and the pathogenesis of protein-uria. Contrib Nephrol 24: 30-41, 1981.
50. Russo PA and Bendayan M. Distribution of endogenous albumin in the glomerular wall of proteinuric patients. Am J Pathol 137: 1481-1490, 1990.
51. Sabbatini M, Sansone G, Uccello F, Giliberti A, Conte G, and Andreucci VE. Early glycosylation products induce glomerular hyperfiltration in normal rats. Kidney Int 42: 875-881, 1992.
52. Salonen JT, Ylä-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssonen K, Palinski W, and Witztum JL. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 339: 883-887, 1992.
53. Sampietro T, Bertuglia S, Colantuoni A, Bionda A, Lenzi S, and Donato L. Increased permeability of hamster microcirculation to glycosylated albumin. Lancet 1: 994-996, 1987.
54. Schnitzer JE, Sung A, Horvat R, and Bravo J. Preferential interaction of albumin-binding proteins, gp30 and gp18, with conformationally modified proteins. Presence in many cells and tissues with a possible role in catabolism. J Biol Chem 267: 24544-24563, 1992.
55. Schurek HJ, Neumann KH, Flohr H, Zeh M, and Stolte H. The physiological and pathophysiological basis of glomerular permeability for plasma proteins and erythrocytes. Eur J Clin Chem Clin Biochem 30: 627-633, 1992.
56. Sharma M, Sharma R, McCarthy ET, and Savin VJ. The focal segmental glomerulosclerosis permeability factor: biochemical characteristics and biological effects. Exp Biol Med 229: 85-98, 2004.
57. Sharma M, Sharma R, McCarthy ET, and Savin VJ. "The FSGS factor:" enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma. J Am Soc Nephrol 10: 552-561, 1999.
58. Svensjo E, Boschcov P, Ketelhuth DF, Jancar S, and Gidlund M. Increased microvascular permeability in the hamster cheek pouch induced by oxidized low density lipoprotein (oxLDL) and some fragmented apolipoprotein B proteins. Inflamm Res 52: 215-220, 2003.
59. Tuma DJ. Role of malondialdehyde-acetaldehyde adducts in liver injury. Free Radic Biol Med 32: 303-308, 2002.
60. Udenfriend S, Stein S, Bohlen P, Dairman W, Leimgruber W, and Weigele M. Fluorescamine: a reagent for assay of amino acids, peptides, proteins, and primary amines in the picomole range. Science 178: 871-872, 1972.
61. Vay D, Parodi M, Rolla R, Mottaran E, Vidali M, Bellomo G, and Albano E. Circulating antibodies recognizing malondialdehyde-modified proteins in healthy subjects. Free Radic Biol Med 30: 277-286, 2001.
62. Viberti G, Mackintosh D, and Keen H. Determinants of the penetration of proteins through the glomerular barrier in insulin-dependent diabetes mellitus. Diabetes 32, Suppl 2: 92-95, 1983.
63. Wautier JL and Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 27: 535-542, 2001.
64. Williams SK, Devenny JJ, and Bitensky MW. Micropinocytic ingestion of glycosylated albumin by isolated microvessels: possible role in pathogenesis of diabetic microangiopathy. Proc Natl Acad Sci USA 78: 2393-2397, 1981.
65. Yamasaki Y, Hisazumi J, Yamaoka K, and Takakura Y. Efficient scavenger receptor-mediated hepatic targeting of proteins by introduction of negative charges on the proteins by aconitylation: the influence of charge density and size of the proteins molecules. Eur J Pharm Sci 18: 305-312, 2003.